This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Brand Names
- Dengvaxia
- Generic Name
- Cyd dengue virus serotype 2 live (attenuated) antigen
- DrugBank Accession Number
- DB15522
- Background
Not Available
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur Inc. 2022-06-08 Not applicable EU 
DENGVAXIA Cyd dengue virus serotype 2 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (100000 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur Inc. 2019-10-01 Not applicable Italy 
Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur Inc. 2022-06-08 Not applicable EU Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur Inc. 2022-06-08 Not applicable EU DENGVAXIA Cyd dengue virus serotype 2 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (100000 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (100000 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur Inc. 2019-10-01 Not applicable Italy
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FH5SVG7GLC
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Dengue Fever 1 somestatus stop reason just information to hide Not Available Completed Not Available Dengue Virus Infection 1 somestatus stop reason just information to hide 3 Completed Prevention Dengue Fever / Dengue Hemorrhagic Fever / Human Papillomavirus Disease 2 somestatus stop reason just information to hide 3 Terminated Prevention Dengue Fever / Dengue Hemorrhagic Fever 1 somestatus stop reason just information to hide 2 Completed Prevention Dengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension; kit Subcutaneous Injection, powder, for suspension Subcutaneous 5.25 log10 CCID50/dose Injection, powder, for suspension Subcutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 09, 2019 19:53 / Updated at June 12, 2020 16:53